A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multi-centre, open-label, single-arm, stratified, exploratory, Phase 2
study evaluating the efficacy and safety of 177Lu-DOTATATE in combination with nivolumab in
adult patients with Grade 3 neuroendocrine tumours (NET) or neuroendocrine carcinomas (NEC).